Clinical trials
Active, not recruiting Colorectal Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
326 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 8 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 12 |
| 2016 | 10 |
| 2017 | 11 |
| 2018 | 18 |
| 2019 | 28 |
| 2020 | 33 |
| 2021 | 35 |
| 2022 | 44 |
| 2023 | 43 |
| 2024 | 42 |
| 2025 | 23 |
| 2026 | 8 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 326 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 17 |
| National Cancer Institute (NCI) | 14 |
| City of Hope Medical Center | 6 |
| University of Southern California | 6 |
| Memorial Sloan Kettering Cancer Center | 5 |
| Novartis Pharmaceuticals | 5 |
| Pfizer | 5 |
| Sun Yat-sen University | 5 |
| AbbVie | 4 |
| AstraZeneca | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Colorectal Neoplasms | 326 |
| Carcinoma, Non-Small-Cell Lung | 55 |
| Breast Neoplasms | 39 |
| Colonic Neoplasms | 38 |
| Neoplasms | 33 |
| Pancreatic Neoplasms | 33 |
| Stomach Neoplasms | 33 |
| Lung Neoplasms | 28 |
| Ovarian Neoplasms | 26 |
| Rectal Neoplasms | 26 |
Trials
Showing 26 to 50 of 326. Each trial links to its page on Pharma Observatory.
226 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.